CBDG - THC Farmaceuticals, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.3850
0.0000 (0.00%)
At close: 9:30AM EDT
Stock chart is not supported by your current browser
Previous Close0.3850
Open0.3850
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.3850 - 0.3850
52 Week Range0.3000 - 4.2000
Volume2,749
Avg. Volume5,452
Market Cap7.498M
Beta (3Y Monthly)1.99
PE Ratio (TTM)N/A
EPS (TTM)-0.0050
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • ACCESSWIRE

    CBDual Biotechnology Corp (subsidiary of OTC: CBDG) to Offer ORALDNA(R) Testing to Improve Oral and Systemic Health

    THOUSAND OAKS, CA / ACCESSWIRE / August 9, 2019 / CBDual Biotechnology Corp., a subsidiary of THC Farmaceuticals, Inc (OTC PINK:CBDG) developer of CBD based oral health products, today announced - that the Company is now offering a powerful new tool to help with gum disease diagnosis and treatment. A simple rinse test from OralDNA® Labs identifies individual genetic susceptibility to periodontal disease. All salivary diagnostic tests can be ordered from the same simple oral rinse collection, disease-causing bacteria and helps personalize doctor prescribed treatment.

  • ACCESSWIRE

    THC Farmaceuticals Receives Patent Protection in Republic of South Africa For Methods of Producing Antibody- Rich Cannabis and Honeysuckle Plants

    THOUSAND OAKS, CA / ACCESSWIRE / June 12, 2019 / CBDual Biotechnology Corp., a subsidiary of THC Farmaceuticals, Inc (OTC PINK: CBDG) today announced that its parent company has been granted patent protection for the South African Patent Application No. 2017/01966 regarding the parent company's Methods of Producing Antibody- Rich Cannabis and Honeysuckle Plants. South African Republic's Patent Office has scheduled publication of this international patent for June 26, 2019. This invention relates generally to the production of antibody-rich cannabis and honeysuckle plants.

  • ACCESSWIRE

    THC Farmaceuticals Acquires Fifty Percent Interest In 78 Acres of California Land; Through Subsidiary CBDual Biotech Begins Retailing Charlotte’s Web CBD Rich Products; To Begin Clinical Trials

    THOUSAND OAKS, CA / ACCESSWIRE / March 6, 2019 / THC Farmaceuticals, Inc. (OTC PINK: CBDG) today announced that it completed the acquisition of a 50% interest in a corporation that owns 78 acres of land in Southern California. THC Farmaceuticals, Inc. also became an authorized retailer for products from CW California, Inc., a wholesale distributor of premium hemp supplements and preferred distributor of the World's Most Trusted Hemp ExtractTM product line ''Charlotte's WebTM'', as well as Elixinol, Myriams Hope, Topikal CBD, and Canniatric. The company's facility is located in southern California, where we provide easy access for patients to participate in clinical trials of new medical cannabis medications, therapies, and products.

  • ACCESSWIRE

    THC Farmaceuticals Completes Acquisition of Majority Ownership of CBDual Biotechnology Corp; Applies for Provisional Patent

    THOUSAND OAKS, CA / ACCESSWIRE / October 17, 2018 / THC Farmaceuticals, Inc. (OTC PINK: CBDG) announces that it has completed the acquisition of a majority ownership in CBDual Biotechnology Corp., a start-up biotech company focused on the development of proprietary products containing CBD (cannabidiol) and/or THC (Tetrahydrocannabinol). Per the agreement, THC Farmaceuticals has committed $250,000 USD in funding and has issued 1,500,000 common shares to CBDual Biotechnology, completing the first phase of the acquisition. The funding, which has begun, and is paid in tranches, will enable CBDual Biotechnology to further implement its operations.